间变性淋巴瘤激酶抑制剂不良反应管理西南专家建议(2021年版)  

Recommendations from Experts in the Management of Adverse Reactions to ALK Inhibitors(2021 Version)

作　　者：王可[1] 李娟[2] 孙建国 李力 张西[5] 张建勇 余敏[7] 叶贤伟[8] 张明[9] 张瑜[10] 姚文秀[2] 黄媚娟[7] Ke WANG;Juan LI;Jianguo SUN;Li LI;Xi ZHANG;Jianyong ZHANG;Min YU;Xianwei YE;Ming ZHANG;Yu ZHANG;Wenxiu YAO;Meijuan HUANG(Department of Respiratory and Critical Care Medicine,West China Hospital of Sichuan University,Chengdu 610041,China;Department of Oncology,Sichuan Cancer Hospital,Chengdu 610041,China;Department of Oncology,Xinqiao Hospital,Army Military Medical University,Chongqing 400037,China;Department of Respiratory and Critical Care Medicine,Army Special Medical Center(Daping Hospital),Chongqing 400042,China;Department of Oncology,Chengdu Third People's Hospital,Chengdu 610000,China;Department of Respiratory and Critical Care Medicine,Affiliated Hospital of Zunyi Medical University,Zunyi 563000,China;Department of Thoracic Oncology,West China Hospital of Sichuan University,Chengdu 610041,China;Department of Respiratory and Critical Care Medicine,Guizhou Provincial People's Hospital,Guiyang 550002,China;Department of Radiation Therapy,Yunnan Cancer Hospital,Kunming 650118,China;Department of Oncology,Guizhou Provincial People's Hospital,Guiyang 550002,China)

机构地区：[1]四川大学华西医院呼吸与危重症医学科,成都610041 [2]四川省肿瘤医院肿瘤内科,成都610041 [3]陆军军医大学新桥医院肿瘤科,重庆400037 [4]陆军特色医学中心(大坪医院)呼吸与危重症医学科,重庆400042 [5]成都市第三人民医院肿瘤科,成都610000 [6]遵义医科大学附属医院呼吸与危重症医学科,遵义563000 [7]四川大学华西医院胸部肿瘤科,成都610041 [8]贵州省人民医院呼吸与危重症医学科,贵阳550002 [9]云南省肿瘤医院放射治疗科,昆明650118 [10]贵州省人民医院肿瘤科,贵阳550002

出　　处：《中国肺癌杂志》2021年第12期815-828,共14页Chinese Journal of Lung Cancer

摘　　要：间变性淋巴瘤激酶(anaplastic lymphoma kinase,ALK)融合基因作为肿瘤驱动基因,对非小细胞肺癌(non-small cell lung cancer,NSCLC)的发生和发展至关重要,而靶向ALK融合基因已成为ALK阳性NSCLC患者的主要治疗手段。第一、二代ALK抑制剂(ALK inhibitor,ALKi)克唑替尼、塞瑞替尼、阿来替尼、恩沙替尼已在中国上市并广泛应用。然而,针对ALKi不良反应尚无统一的管理指导规范,在一定程度上降低甚至限制了ALKi的临床使用及患者获益。本文由四川省肿瘤学会肺癌专业委员会及四川省肿瘤性疾病医疗质量控制中心牵头,针对国内已经获批上市的ALKi,参考国内外临床研究和相关文献,并结合专家实践经验,总结出《ALKi不良反应管理专家建议(2021年版)》,以期为临床提供切实可行的ALKi不良反应的管理策略。Anaplastic lymphoma kinase(ALK)fusion gene,as a tumor driver gene,was crucial for the occurrence and development of non-small cell lung cancer(NSCLC).Recently,targeted ALK fusion gene has become the main treatment method for ALK-positive NSCLC.The first and second generation ALK inhibitors(ALKi),such as crizotinib,ceritinib,alectinib and ensartinib have been approved in China.However,there was no guidance for the management of ALKi adverse reactions.Therefore,this"Recommendations from experts in the management of adverse reactions to ALK inhibitors(2021 version)"has been summarized,led by Lung Cancer Professional Committee of Sichuan Cancer Society and Sichuan Medical Quality Control Center for Tumor Diseases,to provide practical and feasible strategies for clinical ALKi management specification of adverse reactions.

关 键 词：间变性淋巴瘤激酶抑制剂 肺肿瘤 不良反应 专家建议 

分 类 号：R969.3[医药卫生—药理学]